Torisel - 2007 FDA approvals

Drug: Torisel (temsirolimus)
Indication: Renal cell carcinoma
Company: Wyeth
Approval Date: May 30, 2007

Scoop: Torisel is an mTOR inhibitor. In in vitro studies using cancer cells, mTOR inhibition blocked the translation of genes that regulate the cell cycle. Torisel improved median overall survival by 49 percent in Phase III compared to interferon-alpha.

More news:
FDA approves Wyeth's Torisel. Report
Wyeth looking for Torisel approvals. Report

Torisel - 2007 FDA approvals
Read more on

Suggested Articles

Karen DeSalvo's appointment is the latest in a string of hires that deepen the tech giant’s investment in and focus on healthcare.

Spring Bank’s hepatitis B drug, given in tandem with Gilead’s Vemlidy, tamped down on chronic disease in 23% of patients in a phase 2 study.

Verseau will use the money to start testing its macrophage checkpoint modulators in humans.